Evidence map›Paper›PMID 26755751›Full record

ArticleTechnology in cancer research & treatment2017

Norcantharidin Inhibits SK-N-SH Neuroblastoma Cell Growth by Induction of Autophagy and Apoptosis.

Zeping Han, Baoxia Li, Juanjuan Wang, Xiangqiang Zhang, Zhenhua Li, Liting Dai, Mingrong Cao, Jianwei Jiang

Open access · bronzeAbstract read
In one paragraph

Article in Technology in cancer research & treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Zeping Han1 Department of Laboratory, Central Hospital of Panyu, Guangzhou, China.
Baoxia Li2 State Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Juanjuan Wang3 Department of Biochemistry, Medical College, Jinan University, Guangzhou, China.
Xiangqiang Zhang3 Department of Biochemistry, Medical College, Jinan University, Guangzhou, China.
Zhenhua Li3 Department of Biochemistry, Medical College, Jinan University, Guangzhou, China.
Liting Dai3 Department of Biochemistry, Medical College, Jinan University, Guangzhou, China.
Mingrong Cao4 Department of General Surgery, First Affiliated Hospital, Jinan University, Guangzhou, China.
Jianwei Jiang3 Department of Biochemistry, Medical College, Jinan University, Guangzhou, China.
Jinan University · CNFirst Affiliated Hospital of Jinan University · CNPanyu District Central Hospital · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Norcantharidin, a low-toxic analog of the active anticancer compound cantharidin in Mylabris, can inhibit proliferation and induce apoptosis of multiple types of cancer cells. However, the anticancer activities of norcantharidin with respect to neuroblastoma, and its underlying mechanisms, have not been investigated. Therefore, our study was designed to determine the efficacy of norcantharidin on SK-N-SH neuroblastoma cell death and to elucidate detailed mechanisms of activity. In the present study, norcantharidin suppressed the proliferation and cloning ability of SK-N-SH cells in a dose-dependent manner, apparently by reducing the mitochondrial membrane potential and arresting SK-N-SH cells at the G2/M stage, accompanied by elevated expressions of p21 and decreased expressions of cyclin B1 and cell division control 2. Treatment by norcantharidin induced significant mitophagy and autophagy, as demonstrated by a decrease in Translocase Of Outer Mitochondrial Membrane 20 (TOM20), increased beclin1 and LC3-II protein expression, reduced protein SQSTM1/p62 expression, and accumulation of punctate LC3 in the cytoplasm of SK-N-SH cells. In addition, norcantharidin induced apoptosis through regulating the expression of B-cell lymphoma 2-associated X protein/B-cell lymphoma 2 and B-cell lymphoma 2-associated X protein/myeloid cell leukemia 1 and activating caspase-3 and caspase-9-dependent endogenous mitochondrial pathways. We also observed an increase in phosphor-AMP-activated protein kinase accompanied with a decrease in phosphor-protein kinase B and mammalian target of rapamycin expression after treatment with norcantharidin. Subsequent studies indicated that norcantharidin participates in cellular autophagy and apoptosis via activation of the c-Jun NH2-terminal kinases/c-Jun pathway. In conclusion, our results demonstrate that norcantharidin can reduce the mitochondrial membrane potential, induce mitophagy, and subsequently arouse cellular autophagy and apoptosis; the AMP-activated protein kinase, protein kinase B/mammalian target of rapamycin, and c-Jun NH2-terminal kinases/c-Jun signaling pathways are widely involved in these processes. Thus, the traditional Chinese medicine norcantharidin could be a novel therapeutic strategy for treating neuroblastoma.

Indexed as

Antineoplastic AgentsApoptosisAutophagyBridged Bicyclo Compounds, HeterocyclicCell CycleCell Cycle ProteinsCell Line, TumorCell ProliferationGene ExpressionHumansImmunohistochemistryMembrane Potential, MitochondrialNeuroblastomaSignal TransductionAntineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicCell Cycle ProteinsnorcantharidinapoptosisautophagyneuroblastomanorcantharidinSK-N-SH cells line

Identifiers

PMID26755751
PMCPMC5616112
OpenAlexW2337881909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.